Opendata, web and dolomites

Capsulight

The first ingestible capsule for eradicating Helicobacter pylori infection through photodynamic therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Capsulight project word cloud

Explore the words cloud of the Capsulight project. It provides you a very rough idea of what is the project "Capsulight" about.

mix    pharmacological    patented    unparalleled    eradicated    light    reaching    gastric    florence    preliminary    30    off    national    photobiology    optimize    centers    cured    healthcare    sant    tests    device    bacterium    scuola    eradicate    biopsy    capsule    power    medicine    diagnosed    proton    biopsies    university    despite    intragastric    mass    efficacy    photodynamic    world    posology    drug    savings    unfortunately    ingestible    killing    therapy    validation    market    pump    stomach    infected    therapies    drugs    hospitalization    gastroenterology    reducing    robotics    miniaturization    inhibitor    safety    assumption    usually    infection    resistance    attributable    advantages    endoscopic    anna    vitro    economic    presented    rate    helicobacter    antibiotic    97    mark    90    secondary    showed    once    possibility    cancers    first    70    50    spin    clinical    pylori    capsulight    countries    carcinogen    agent    microbiology    undergo    cycles    diagnostic    probiomedica    superiore    treatment    capsules    specialized    ce    population   

Project "Capsulight" data sheet

The following table provides information about the project.

Coordinator
PROBIOMEDICA SRL 

Organization address
address: VIA DI BELLOSGUARDO 2 ROSSO
city: FIRENZE
postcode: 50124
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website https://www.probiomedica.it
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PROBIOMEDICA SRL IT (FIRENZE) coordinator 50˙000.00

Map

 Project objective

Helicobacter pylori (H. pylori) is a bacterium of the stomach which affects on average 50% of the world population, reaching up to 70% in some European Countries. Once it is diagnosed, it has to be eradicated, since it is a carcinogen agent and around 90% of all gastric cancers can be attributable to its infection. The only available treatment is a pharmacological therapy based on the assumption of proton-pump inhibitor and a mix of 2-3 antibiotic drugs. Unfortunately, due to increasing antibiotic resistance, up to 30% of the affected population cannot be cured, despite several cycles of antibiotic therapy and usually endoscopic biopsy to determine antibiotic-resistance. Probiomedica is a spin-off of the University of Florence and Scuola Superiore Sant’Anna specialized in photobiology and robotics applied to medicine, which has developed and patented CapsuLight, the first ingestible capsule able to eradicate H. Pylori infection through intragastric photodynamic therapy, that is through the power of light. The device is based on the established technology and safety of endoscopic capsules for diagnostic use, and our preliminary in vitro tests showed 97% efficacy in killing the bacterium. The advantages for infected population are unparalleled: the possibility to eradicate the bacterium for those who cannot be cured due to antibiotic resistance (our first target market); the higher efficacy rate, no side effects due to antibiotic cycles, and easy posology for all the infected population (secondary market). CapsuLight will also provide high economic savings to National Healthcare Systems, by reducing drug therapies cycles and endoscopic biopsies and related costs for hospitalization. Probiomedica has already presented the product to several gastroenterology and microbiology centers and will optimize the capsule design for further miniaturization and mass production, and to undergo the necessary clinical validation for getting the CE mark during the Phase 2 project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAPSULIGHT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAPSULIGHT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More